Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 10, No. 9, 665-685, October 2005; doi:10.1634/theoncologist.10-9-665
© 2005 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eniu, A.
Right arrow Articles by Perez, E. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eniu, A.
Right arrow Articles by Perez, E. A.

Weekly Administration of Docetaxel and Paclitaxel in Metastatic or Advanced Breast Cancer

Alexandru Eniua, Frances M. Palmierib, Edith A. Perezb

a Cancer Institute, Ion Chiricuta Cluj-Napoca, Romania; b Mayo Clinic and Mayo Foundation, Jacksonville, Florida, USA

Key Words. Breast cancer • Metastatic disease • Taxanes • Chemotherapy

Correspondence: Edith A. Perez, M.D., Multidisciplinary Breast Clinic, Mayo Clinic, 4500 San Pablo Road Jacksonville, Florida 32224, USA. Telephone: 904-953-7283; Fax: 904-953-1412; e-mail: perez.edith{at}mayo.edu

The taxanes docetaxel (Taxotere®; Aventis Pharmaceuticals Inc., Bridgewater, NJ, http://www.aventispharma-us.com) and paclitaxel (Taxol®; Bristol-Myers Squibb, Princeton, NJ, http://www.bms.com) have significant clinical activity in metastatic breast cancer. A number of clinical trials have evaluated the tolerability and efficacy of weekly taxane administration to optimize the benefit-to-risk ratio in metastatic breast cancer. Single-agent studies with docetaxel and paclitaxel in metastatic breast cancer show clinically significant antitumor activity even in advanced, heavily pretreated, resistant, and/or refractory disease. This activity is also evident with taxane-based combination regimens. Severe hematologic and nonhematologic toxicities are infrequent, with other toxicities noted based on the dose and weekly regimen selected. Weekly docetaxel and paclitaxel regimens represent valuable therapeutic options for women with metastatic breast cancer and have entered evaluation as part of adjuvant therapy for this disease.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
F. Galimberti, S. L. Thompson, X. Liu, H. Li, V. Memoli, S. R. Green, J. DiRenzo, P. Greninger, S. V. Sharma, J. Settleman, et al.
Targeting the Cyclin E-Cdk-2 Complex Represses Lung Cancer Growth by Triggering Anaphase Catastrophe
Clin. Cancer Res., January 1, 2010; 16(1): 109 - 120.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H. Joensuu, L. Sailas, T. Alanko, K. Sunela, R. Huuhtanen, M. Utriainen, R. Kokko, P. Bono, T. Wigren, S. Pyrhonen, et al.
Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial
Ann. Onc., October 9, 2009; (2009) mdp397v1.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
A. Moreno-Aspitia and E. A. Perez
Treatment Options for Breast Cancer Resistant to Anthracycline and Taxane
Mayo Clin. Proc., June 1, 2009; 84(6): 533 - 545.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
J. HORIGUCHI, T. OYAMA, Y. KOIBUCHI, T. YOKOE, D. TAKATA, F. IKEDA, H. NAGAOKA, N. ROKUTANDA, R. NAGAOKA, Y. ISHIKAWA, et al.
Neoadjuvant Weekly Paclitaxel with and without Trastuzumab in Locally Advanced or Metastatic Breast Cancer
Anticancer Res, February 1, 2009; 29(2): 517 - 524.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Ardavanis, P. Kountourakis, F. Kyriakou, S. Malliou, I. Mantzaris, A. Garoufali, I. Yiotis, A. Scorilas, N. Baziotis, and G. Rigatos
Trastuzumab plus Paclitaxel or Docetaxel in HER-2-Negative/HER-2 ECD-Positive Anthracycline- and Taxane-Refractory Advanced Breast Cancer
Oncologist, April 1, 2008; 13(4): 361 - 369.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. T. Jun, J. Sun, K. Rex, R. Radinsky, R. Kendall, A. Coxon, and T. L. Burgess
AMG 102, A Fully Human Anti-Hepatocyte Growth Factor/Scatter Factor Neutralizing Antibody, Enhances the Efficacy of Temozolomide or Docetaxel in U-87 MG Cells and Xenografts
Clin. Cancer Res., November 15, 2007; 13(22): 6735 - 6742.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. Aneja, J. Zhou, B. Zhou, R. Chandra, and H. C. Joshi
Treatment of hormone-refractory breast cancer: apoptosis and regression of human tumors implanted in mice.
Mol. Cancer Ther., September 1, 2006; 5(9): 2366 - 2377.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2005 by AlphaMed Press.
Advertisement